Surveillance for Leishmaniasis Skin Lesions in Mali
NCT00344084 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1593
Last updated 2019-11-08
Summary
This study will examine why some people who become infected with the leishmaniasis parasite develop skin lesions and others do not. The parasite that causes leishmaniasis is transmitted by the bite of a sandfly. It can cause skin lesions that may persist for several months, spread to other parts of the body, and become infected with bacteria. Treated with medicine, leishmaniasis can be cured completely.
People 1 year of age and older who live in the Mali villages of Kemena or Sougoula may be eligible for this study.
Participants are injected with a small amount of inactive parasites into the skin of their arm. People who have a reaction to the test, and thus have been exposed to the parasite, are examined for skin lesions. Their lesions, if any, are evaluated and treated, and their participation in the study ends.
Participants who do not react to the skin test are examined for skin lesions every month for 5 months. Those who are 18 years of age or older and have mild leishmaniasis skin lesions may have a small amount of fluid injected into a lesion in order to remove parasites for laboratory analysis.
Patients' lesions may be photographed to compare what they look like before and after treatment. Lesions are treated with an ointment containing an antibiotic and a disinfectant twice a day for 20 days. The lesions are examined 1 and 3 weeks after treatment is completed to see if the disease has been cured. A few months later, the skin test is repeated to determine whether the person has been exposed to parasites over the past year.
A blood sample may be drawn from some participants, depending on whether they have a reaction to the second skin test and whether they have developed skin lesions. The sample is drawn only from patients 18-65 years of age.
Some blood drawn for the study may be used for genetic tests.
Conditions
- Cutaneous Leishmaniasis
Sponsors & Collaborators
-
National Institute of Allergy and Infectious Diseases (NIAID)
lead NIH
Principal Investigators
-
Rick M Fairhurst, M.D. · National Institute of Allergy and Infectious Diseases (NIAID)
Eligibility
- Min Age
- 1 Year
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2006-03-16
- Completion
- 2012-09-17
Countries
- Mali
Study Locations
More Related Trials
-
Safety Study to Evaluate the Leish-111f + MPL-SE Vaccine in the Prevention of Cutaneous Leishmaniasis in Healthy Subjects Previously Exposed to the Leishmania Parasite
NCT00121849 ·Status: COMPLETED ·Phase: PHASE1
-
Immune Responses After Human Subject Challenge With Sand Fly Bites
NCT01289977 ·Status: COMPLETED
-
Study to Evaluate the Leish-111f + MPL-SE Vaccine in Healthy Adults Not Previously Exposed to Leishmania Parasite
NCT00121862 ·Status: COMPLETED ·Phase: PHASE2
-
Investigation of an Outbreak Situation of Cutaneous Leishmaniasis Among Military Personnel in French Guiana (CEFELEISH)
NCT04888130 ·Status: COMPLETED
-
A Clinical Study to Develop a Controlled Human Infection Model Using Leishmania Major-infected Sand Flies
NCT04512742 ·Status: COMPLETED ·Phase: NA
-
A Study to Explore Association of Treatment Regimens for Visceral Leishmaniasis, Host Immunological, Genetical and Nutrition Factors With Post-kala-azar Dermal Leishmaniasis (PKDL)
NCT01975051 ·Status: COMPLETED ·Phase: PHASE4
-
Liposomal Amphotericin in Disseminated Leishmaniasis
NCT02025491 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Cases of Cutaneous Leishmaniasis Treated With Miltefosine in French Guiana, Retrospective Study
NCT05493059 ·Status: UNKNOWN
-
Clinical Investigation of Infections Due to Leishmanial Parasites
NCT00001169 ·Status: COMPLETED
-
Trial of Miltefosine in Cutaneous Leishmaniasis (Brazil)
NCT00600548 ·Status: COMPLETED ·Phase: PHASE2
-
The Association of Miltefosine and Pentoxifylline to Treat Mucosal and Cutaneous Leishmaniasis: A Clinical Trial in Brazil
NCT02530697 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Pilot Study to Estimate the Burden and Distribution of Plasmodium Falciparum Malaria in Kalifabougou, Mali in Preparation for a Prospective Cohort Study of Naturally-Acquired Malaria Immunity
NCT01160562 ·Status: COMPLETED
-
Doxycycline to Treat Mansonella Perstans Infection in Patients With and Without Lymphatic Filariasis
NCT00340691 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Evaluate the Leish-111F + MPL-SE Vaccine in the Treatment of Mucosal Leishmaniasis
NCT00111514 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy Trial on Oral Miltefosine in Comparison With Glucantime in the Treatment of ACL Caused by L. Tropica
NCT00351520 ·Status: COMPLETED ·Phase: PHASE3
-
Expression of Mif Alleles in Individuals With Leishmaniasis
NCT00401349 ·Status: COMPLETED
-
A Study of the Efficacy and Safety of the LEISH-F2 + MPL-SE Vaccine for Treatment of Cutaneous Leishmaniasis
NCT01011309 ·Status: COMPLETED ·Phase: PHASE2
-
Immune Response Regulation in People Infected Concurrently With Malarial and Filarial Parasites
NCT00341666 ·Status: COMPLETED
-
Pilot Study: Oral Treatment of American Tegumentary Leishmaniasis (Cutaneous and Mucosal Forms) in the Elderly
NCT06040489 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
ASYMPTOMATIC CARRIER OF LEISHMANIA INFANTUM, MEDISERRANEAN VISCERAL LEISHMANIOSIS AGENT: STUDY OF IMMUNE RESPONSE -
NCT03303898 ·Status: COMPLETED ·Phase: NA
-
Analysis of the Immune Response to the Malaria Parasite in Mali, West Africa
NCT00346346 ·Status: COMPLETED
-
Topical Sm29 in Combination With Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis.
NCT06000514 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Safety and Immunogenicity of the LEISH-F2 + MPL-SE Vaccine With SSG for Patients With PKDL
NCT00982774 ·Status: COMPLETED ·Phase: PHASE1
-
Assessment of Biologic Parameters in Preparation for Future Malaria Vaccine Trials in Don gu Bougou, Mali
NCT00341783 ·Status: TERMINATED
-
Open-Label Safety Study of Three-Antigen Leishmania Polyprotein With Adjuvant MPL-SE in Healthy Adults in India
NCT00486382 ·Status: COMPLETED ·Phase: PHASE1